← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications (1031)

• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Recent insights regarding the molecular basis of myeloproliferative neoplasms. (2020/01/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF). (2020/01/01) ♡
• Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. (2020/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Autoimmune myelofibrosis associated with systemic lupus erythematosus: a case report. (2020/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche). (2020/01/01) ♡
• [Recent advances in the treatment of myelofibrosis]. (2020/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A case report of a rare omental extramedullary hematopoiesis in an adult: 'an idiopathic finding'. (2019/12/31) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. (2019/12/26) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. (2019/12/26) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Primary hypertrophic osteoarthropathy related gastrointestinal complication has distinctive clinical and pathological characteristics: two cases report and review of the literature. (2019/12/26) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis. (2019/12/24) ♡
• Evaluation of the JAK2V617F Mutational Burden in Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms: A Single-center Experience. (2019/12/21) ♡
• Scherber RM, Mesa RA. Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF. Hematology Am Soc Hematol Educ Program. 2018;2018:118-126. (2019/12/06) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN. (2019/12/06) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. (2019/12/06) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Hydroxyurea-induced cutaneous squamous cell carcinoma: A case report. (2019/12/06) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. (2019/12/05) ♡
• Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study. (2019/12/04) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Infliximab as effective treatment for aseptic neutrophilic myositis. (2019/12/03) ♡
• A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. (2019/12/02) ♡
• TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients. (2019/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A megakaryocyte in a peripheral blood smear. (2019/12/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice. (2019/12/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms. (2019/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Development of myelofibrosis and acute monocytic leukemia in a patient with hereditary spherocytosis: A case report. (2019/12/01) ♡
• EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis. (2019/12/01) ♡
• Decreased Activity of Blood Acid Sphingomyelinase in the Course of Multiple Myeloma. (2019/11/30) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. (2019/11/28) ♡
• The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN. (2019/11/26) ♡
• Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. (2019/11/26) ♡
• Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. (2019/11/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Cementless bipolar hemiarthroplasty in a patient with PMF: a case report. (2019/11/15) ♡
• Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. (2019/11/12) ♡
• Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms. (2019/11/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. (2019/11/07) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. JAK-inhibitors in dermatology: current evidence and future applications. (2019/11/01) ♡
• Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients. (2019/11/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Myelofibrosis associated with systemic lupus erythematosus successfully treated with rituximab. (2019/11/01) ♡
• Myelofibrosis in Patients of Chronic Myeloid Leukemia in Chronic Phase at Presentation. (2019/11/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. (2019/11/01) ♡
• The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms. (2019/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?]. (2019/11/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis. (2019/11/01) ♡
• Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms - Impact Of Comorbidity. (2019/11/01) ♡
• Pachydermoperiostosis Associated with Myelofibrosis: A Rare Case Report. (2019/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis. (2019/11/01) ♡
• Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency. (2019/10/24) ♡
• Digital PCR - Methods and Protocols. (2019/10/18) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes. (2019/10/18) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Experimental Modeling of Myeloproliferative Neoplasms. (2019/10/15) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.